David Scadden, MD
Massachusetts General Hospital
The Scadden laboratory focuses on blood, particularly the regulation of the hematopoietic stem cell by its microenvironment or niche. Using a combination of genetics, imaging and pharmacology, the laboratory has defined key components of the niche and how stem cells traffic to and engraft the bone marrow. It has demonstrated methods of altering niche interactions that have resulted in two clinical trials in the use of stem cells to treat hematologic malignancies.
Based on understanding mechanisms by which normal stem cells are governed in normal tissues, the laboratory has emphasized the role of the niche in disease. We have demonstrated the primary role the microenvironment can play in disordered tissue homeostasis and the emergence of malignancy. This work is the basis for investigating niche based approaches to cancer.
David Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University. He is a practicing hematologist/oncologist who focuses on bringing stem cell biology to patient care. He founded and directs the Center for Regenerative Medicine at the Massachusetts General Hospital and with Douglas Melton, co-founded and co-directs the Harvard Stem Cell Institute and the Harvard University Department of Stem Cell and Regenerative Biology. He is a member of the Institute of Medicine of the National Academies of Science, the Board of External Experts for the National Heart, Lung and Blood Institute and a former member of the National Cancer Institute’s Board of Scientific Counselors. He has received multiple honorary degrees, awards and memberships in honorary societies. His work emphasizes targeting the stem cell niche to attain novel therapies for blood diseases.
- New strategy to improve stem cell transplantation
- A non-toxic strategy to treat leukemia
- New map of cell behavior reveals key proteins that cells destroy
- Bone drug kills resistant cancer stem cells by making home unlivable
- Long-lasting blood vessels generated from human iPS cells
- Two HSCI scientists awarded Massachusetts Life Sciences Center grants to research novel therapeutics
- “Good” cells can go “bad” in a “bad neighborhood"
- Mechanism directing stem cells to their destination identified
- Response to federal injunction on stem cell funding
- David Scadden, MD, and Leonard I. Zon, MD, win Hematology Society awards
- Letter from HSCI Scientific Directors